Company intelligence / Profile preview

Eliptica

London, England, United Kingdomeliptica.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

Eliptica is developing a platform to enable next-generation precision medicine by translating high-throughput proteomic technologies and applied machine learning from academic research into routine clinical practice. The company is a spin-out from the Francis Crick Institute and aims to make advanced protein analysis accessible for patient care. No published clinical results or product launches are available yet.

Therapeutic areas: Other
Modalities: Proteomics-based diagnosticsApplied machine learning (for clinical proteomics)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Eliptica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eliptica.

Explore the full profile